Praziquantel

 

 

WHO - Praziquantel has been used successfully over the past 30 years to control schistosomiasis in many countries. The recent increased support for the control of Neglected Tropical Diseases and increased access to praziquantel led to a significant increase in the number of people treated for schistosomiasis. In 2012 more than 35 million people, 83% of them in sub-Saharan Africa, were treated for schistosomiasis. 

     There is growing evidence that very young children become infected with schistosomiasis when taken to water contact sites by their care-givers and siblings. In some situations the prevalence of schistosomiasis infection in these young children is very high. Recent studies have shown that praziquantel, when made palatable for small children, is safe, well tolerated, and effective in the treatment of pre-school children. However inclusion of very young children in mass treatment campaigns could prove disruptive and unsafe as there is currently no appropriate paediatric formulation of praziquantel.